NCT04106583

Brief Summary

The objective of this study is to demonstrate the safety and efficacy of the Penumbra SMART COIL® System, including the WAVE™ Extra Soft Coils (WAVE) as a fill and finish coil, in the treatment of intracranial aneurysms. Imaging will be analyzed by an independent core lab to assess aneurysm occlusion rates and perform a comparative analysis between imaging modalities.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
572

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2019

Typical duration for all trials

Geographic Reach
6 countries

43 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 27, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

November 5, 2019

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 2, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 2, 2023

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

March 4, 2025

Completed
Last Updated

March 4, 2025

Status Verified

February 1, 2025

Enrollment Period

3.7 years

First QC Date

September 25, 2019

Results QC Date

November 21, 2024

Last Update Submit

February 10, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Efficacy: Adequate Occlusion

    Adequate occlusion defined as Raymond-Roy Class I and II at final follow-up Raymond-Roy Class grading ranges I to III higher values represent a worse outcome.

    Through Study Completion, An Average of 1 Year

  • Safety: Serious Adverse Events (SAEs)

    The primary safety endpoints are SAEs within 24 hours post-procedure

    Up to 24 Hours Post-Procedure

  • Safety: Device-Related SAE

    Device-related SAE up to 7 days or discharge

    Through Discharge, up to 7 Days Post-Procedure

Secondary Outcomes (8)

  • Efficacy: Occlusion Rate

    Immediate Post-Procedure

  • Efficacy: Retreatment Rate

    Through Study Completion, An Average of 1 Year

  • Efficacy: Aneurysm Occlusion Raymond I

    Immediate Post-Treatment

  • Efficacy: Aneurysm Occlusion Raymond I

    Through Study Completion, An Average of 1 Year

  • Efficacy: Aneurysm Recanalization or Progressive Thrombosis

    From Immediate Post Procedure Through Study Completion, An Average of 1 Year

  • +3 more secondary outcomes

Study Arms (1)

Single Arm

Single Arm - Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System

Device: WAVE, as part of the SMART COIL System

Interventions

WAVE, as part of the SMART COIL System

Single Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System

You may qualify if:

  • Patient age ≥ 18 years
  • Patient having embolization of intracranial aneurysms
  • WAVE Extra Soft Coil is final finishing coil
  • Penumbra SMART COIL System accounts for at least 75% of total number of coils implanted
  • Informed consent obtained per Institutional Review Board/Ethics Committee (IRB/EC) requirements

You may not qualify if:

  • Life expectancy less than 1 year
  • Patient previously enrolled in the SURF Study
  • Known multiple intracranial aneurysms requiring treatment during index procedure
  • Patient is unwilling or unable to comply with protocol follow up schedule and/or based on the Investigator's judgment the patient is not a good study candidate
  • Participation in an interventional drug or device study that may confound the results of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (43)

Southeast Health Medical Center

Dothan, Alabama, 36301, United States

Location

Banner UMC Tucson

Tucson, Arizona, 85719, United States

Location

Sharp Grossmont

La Mesa, California, 91942, United States

Location

Los Robles

Thousand Oaks, California, 91360, United States

Location

HRI - Swedish

Englewood, Colorado, 80113, United States

Location

St. Anthony's Hospital

Lakewood, Colorado, 80228, United States

Location

Yale New Haven

New Haven, Connecticut, 06320, United States

Location

University of Miami (Jackson Memorial)

Miami, Florida, 33136, United States

Location

University of South Florida

Tampa, Florida, 33606, United States

Location

Morton Plant

Tampa, Florida, 33756, United States

Location

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

Amita Health

Joliet, Illinois, 60435, United States

Location

Indiana University Health

Indianapolis, Indiana, 46202, United States

Location

Ochsner Medical Center

New Orleans, Louisiana, 70121, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Metro Health

Wyoming, Michigan, 49519, United States

Location

SSM Health Care

Bridgeton, Missouri, 63044, United States

Location

Northwell Health

Manhasset, New York, 11030, United States

Location

Mount Sinai Hospital

New York, New York, 10029, United States

Location

Westchester Medical Center

Valhalla, New York, 10595, United States

Location

Vidant Medical Center

Greenville, North Carolina, 27834, United States

Location

Mercy St. Vincent

Toledo, Ohio, 43608, United States

Location

University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States

Location

Geisinger Medical Center

Danville, Pennsylvania, 17822, United States

Location

UPenn

Philadelphia, Pennsylvania, 19104, United States

Location

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States

Location

MUSC

Charleston, South Carolina, 29425, United States

Location

Greenville Memorial Hospital

Greenville, South Carolina, 29605, United States

Location

University of Tennessee Medical Center, Knoxville

Knoxville, Tennessee, 37996, United States

Location

Baylor University Medical Center

Dallas, Texas, 75246, United States

Location

McAllen Medical Center

McAllen, Texas, 78503, United States

Location

Texas Stroke Institute - DFW

Plano, Texas, 75075, United States

Location

Riverside Regional Medical Center

Newport News, Virginia, 23601, United States

Location

Foothills Medical Center

Calgary, T2N 2T9, Canada

Location

University Health Network

Toronto, M5T 2S8, Canada

Location

Bremen-Mitte

Bremen, Germany

Location

Klinikum Chemnitz gGmbH

Chemnitz, 09116, Germany

Location

UKSH - Campus Lübeck

Lübeck, 23538, Germany

Location

Maggiore della Carità

Novara, Italy

Location

Vall d'Hebron

Barcelona, Spain

Location

Donostia

San Sebastián, Spain

Location

Universitätsspital Basel

Basel, Switzerland

Location

Related Publications (1)

  • Schirmer CM, Yoo AJ, Spiotta AM, Kaminsky I, Alshekhlee A, Starke RM, Nicholson A, Zaidat OO, Bohnstedt B, Psychogios MN, Viets R, Asif KS, Stapleton CJ, Mitha AP, Goren O; SURF Study Investigators. Intracranial aneurysm embolization using Penumbra fill and finish coils: 1-year results of a prospective, real-world, multicenter SURF study. J Neurointerv Surg. 2025 Sep 4:jnis-2025-023633. doi: 10.1136/jnis-2025-023633. Online ahead of print.

MeSH Terms

Conditions

Intracranial Aneurysm

Condition Hierarchy (Ancestors)

Intracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesAneurysmVascular DiseasesCardiovascular Diseases

Results Point of Contact

Title
Brooke Lawson
Organization
Penumbra, Inc.

Study Officials

  • Clemens M Schirmer, MD

    Geisinger Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 25, 2019

First Posted

September 27, 2019

Study Start

November 5, 2019

Primary Completion

August 2, 2023

Study Completion

August 2, 2023

Last Updated

March 4, 2025

Results First Posted

March 4, 2025

Record last verified: 2025-02

Locations